There was no significant difference in response to induction chemotherapy (per the 1993 International Neuroblastoma Response Criteria31 used in the ANBL0532 study) on the basis of ALK, RAS pathway, or ATRX aberration status (Data Supplement, Table S4). This evidence concerns the gene ALK and neuroblastoma.